We have demonstrated that fusions of ethanol-treated tumor cells and DCs stimulated via dual TLRs are highly immunogenic and induce augmented antigen-specific CTL responses in vitro through TGF-β1 blockade and IL-12p70 production. The gene discussed is TGFB1; the disease is neoplasm.